Literature DB >> 9796257

[Nuclear matrix protein 22 levels in patients with renal transplantation].

Y Kagebayashi1, K Yoshida, T Kitauchi, S Kimura, T Yoneda, M Takao, E Okajima, Y Hirao.   

Abstract

BACKGROUND: Nuclear matrix protein 22 (NMP22) is a parameter of cell death including apoptosis. To evaluate the clinical efficacy of NMP22 as a marker for rejection after renal transplantation, we measured serum and urinary NMP22. PATIENTS AND METHODS: We measured the concentrations of serum NMP22 by Konica-Matritech NMP22 kit, and CD3, 4, 8 which are surface markers of lymphocyte, in 11 patients with renal transplantation. The patients consisted of 10 males and 1 females whose serum creatinine ranged 1.0 to 2.7 mg/dl. Additionally, 9 healthy adults were employed as control subjects. And serum and urinary NMP22 were measured after transplantation sequentially in 5 of the patients.
RESULTS: 1) In the patients, serum NMP22 values were higher than those in control subjects, statistically (p < 0.01). 2) There were not significant correlations between serum NMP22 and CD3, 4, 8, 3) At the periods of acute tubular necrosis and acute rejection, serum NMP22 values were higher than those at the stable periods.
CONCLUSIONS: These results suggest that serum NMP22 is useful parameter of rejection in renal transplantation patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796257     DOI: 10.5980/jpnjurol1989.89.774

Source DB:  PubMed          Journal:  Nihon Hinyokika Gakkai Zasshi        ISSN: 0021-5287


  1 in total

1.  Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.

Authors:  Matteo Santoni; Francesco Catanzariti; Daniele Minardi; Luciano Burattini; Massimo Nabissi; Giovanni Muzzonigro; Stefano Cascinu; Giorgio Santoni
Journal:  Adv Urol       Date:  2012-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.